Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: “Modulating IL-13 Activity Using Mutated IL-13 Molecules That Are Antagonists or Agonists of IL-13”, PCT Application PCT/US00/31044 Only written comments and/or license applications that are received by the National Institutes of Health on or before September 15, 2003 will be considered.
View Prospective Grant of Exclusive License: Methods and Devices for Intramuscular Stimulation of Upper Airway and Swallowing Muscle Groups Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 12, 2003 will be considered.
View Prospective Grant of Exclusive License: Vaccine For Protection Against Shigella sonnei Disease Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 8, 2003 will be considered.
View Prospective Grant of Exclusive License: Vaccine Products for Prevention and Treatment of Chronic Hepatitis C Infections (HCV) Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 8, 2003 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Co-Exclusive License: Glycosylation-Resistant Cyanovirins (CV-N) and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Using Nonglycosylated Cyanovirins for Use in Vaccines and Therapeutics Based on CV-N for the Prevention and/or Treatment of Influenza Infection Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before August 19, 2003 will be considered.
View Cooperative Research and Development Agreement
View National Institute of Allergy and Infectious Diseases: Licensing Opportunity and Cooperative Research and Development Agreement (“CRADA”) Opportunity; Live Attenuated Vaccine To Prevent Disease Caused by West Nile Virus Respondents interested in licensing the invention will be required to submit an "Application for License to Public Health Service Inventions" on or before August 11, 2003, for priority consideration.
View Prospective Grant of Co-Exclusive License: Convection Enhanced Drug Delivery for Transforming Growth Factor Alpha (TGFα) Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before July 7, 2003 will be considered.
View Prospective Grant of Exclusive License: The Use of the Domain-Swapped Dimer of Cyanovirin (deltaQ50-CVN) in a Topical Microbicide To Prevent the Transmission of HIV and Other Sexually Transmitted Diseases Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 23, 2003, will be considered.
View Prospective Grant of Exclusive License: The Systemic In Vivo Use of the Domain-Swapped Dimer of Cyanovirin (DeltaQ50-CVN) as a Prophylactic or Therapeutic Against HIV and Enveloped Viruses That Cause Hemorrhagic Fever; the Ex Vivo Use of the Domain-Swapped Dimer of Cyanovirin (DeltaQ50-CVN) To Remove or Inactivate HIV in Fluid Samples Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 23, 2003 will be considered.
View Prospective Grant of Exclusive License: Use of Hydroxyurea Alone and in Combination with dNTP Competitors for Blocking Reverse Transcriptase Dependent Viruses Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before June 17, 2003 will be considered.
View Prospective Grant of Exclusive License: β2 Microglobulin Fusion Proteins and High Affinity Variants Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 16, 2003 will be considered.
View Prospective Grant of Exclusive License: Diagnostics of Fungal Infections 1/12/2001.
View Prospective Grant of Exclusive License: Human Monoclonal Antibody Biotherapeutics for the Treatment of HIV Infections Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 12, 2003 will be considered.
View Prospective Grant of Exclusive License: Protein/Peptide Biotherapeutics for the Treatment of HIV Infections Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 9, 2003, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Protein Biopharmaceuticals for Treatment of HIV Infections Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 5, 2003 will be considered.
View Prospective Grant of Exclusive License: Human Monoclonal Antibody Biotherapeutics for the Treatment of Hepatitis C (HCV) Infections Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 5, 2003 will be considered.
View Cooperative Research and Development Agreement
View Prospective Grant of Exclusive License: Vaccines Against Rotavirus Disease Only written comments and/or applications for a license which are received by NIH on or before April 15, 2003 will be considered.
View Prospective Grant of Exclusive License: Novel Vaccinia Virus Vector for the Treatment of Human Cancers Only written comments and/or license applications which are received by the National Institutes of Health on or before April 14, 2003, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: “Interleukin-2 Receptor and Applications Thereof” Only written comments and/or license applications which are received by the National Institutes of Health on or before April 7, 2003 will be considered.
View Prospective Grant of Exclusive License: “Spatially and Temporal Control of Gene Expression Protein Promoter in Combination with Local Heat” Only written comments and/or license applications which are received by the National Institutes of Health on or before April 7, 2003 will be considered.